Aenitis Technologies Champions Innovation in Bioproduction
Aenitis is leading a revolution in the bioproduction industry by developing scalable, cost-effective, and precise cell processing technologies to meet growing global demands.
Introducing Acoustofluidic Technology
At the heart of Aenitis’s innovations is Mitis™, a flagship product utilizing unique Acoustofluidic Technology. This advanced technology is being adopted across various stages of bioproduction—from research environments to clinical applications. It excels in cell sorting, isolation, concentration, and washing, reflecting a versatile tool for modern biotechnology.
Fundraising for Expansion
Aenitis has successfully attracted significant investment to propel its mission forward. The recent funding round was led by the European Innovation Council Fund, the Quadrivium I fund from Seventure Partners, and Mifani Invest, aimed at supporting commercial launch and facilitating global expansion initiatives.
Funding Milestones and Future Prospects
Recently, Aenitis Technologies has announced the closure of its equity financing, cementing a pivotal position within the deep-tech sector. The financing was advised by the European Investment Bank among other notable investors, culminating in a robust total of €14.5 million in both equity and non-dilutive funding since its inception. This financial backing is vital for advancing Aenitis's technology, particularly for preparing its flagship product, Mitis™, for market readiness.
Strategic Development Initiatives
The capital raised will be pivotal in demonstrating key use cases alongside important industry players, establishing essential distribution networks starting in Europe and expanding into US and selected Asian markets. The funds will also enhance technology development stages, optimizing production lines and refining Mitis™ for broader market application.
Governance and Expertise
To enhance its governance structure, Aenitis welcomed industry veteran Eric Garnier as Independent Chairman of its Strategic Board. With his previous experience as Vice President and General Manager of Pall Medical, Garnier is expected to drive revenue growth and establish strategic partnerships that will pave the way for future advances.
Vision for Innovation in a Competitive Market
With the support of experts like Michel Spagnol from Mifani Invest, the organization is poised to disrupt traditional biomanufacturing processes. Spagnol acknowledges the unique advantages that Aenitis's technology brings to biomanufacturing—namely, enhanced cell processing efficiency and quality.
Pioneering New Pathways in Biomanufacturing
Aenitis Technologies is redefining bioproduction through the implementation of its patented technologies. The company’s foundation lies in its innovative platform based on acoustic levitation, allowing gentle and non-invasive manipulation of cells. This non-contact method minimizes mechanical stress, therefore ensuring enhanced cell viability and functionality during processing.
Commitment to High Standards
The dedication to achieving high-quality results makes Aenitis a front-runner in the fields of cell therapy and biomanufacturing. By actively addressing challenges in scalability and cost-effectiveness, the company is strategically positioned to become a leader in this fast-evolving industry.
Aenitis's Broader Impact
Through its focus on developing unique solutions, Aenitis aims not only to enhance bioproduction but also to set new standards in healthcare and biotechnology. The integration of acoustic waves signifies a contemporary approach to cell manipulation, promising substantial benefits across various biotech applications.
Aenitis is fostering a thriving environment for innovation within its sector, drawing on a wealth of expertise from co-founders with backgrounds in acoustic levitation, fluid mechanics, and biotechnology entrepreneurship. This collaboration has earned the trust and support of significant entities including the European Commission and leading venture capitalists.
Frequently Asked Questions
What is Aenitis Technologies focused on?
Aenitis Technologies specializes in bioproduction innovations, particularly using acoustofluidic technology for cell processing and manipulation.
What is Mitis™?
Mitis™ is Aenitis's flagship product that utilizes unique acoustofluidic technology for cell sorting, isolation, concentration, and washing across various scales.
Who are Aenitis's main investors?
Key investors include the European Innovation Council Fund, Seventure Partners, and Mifani Invest, among others.
How does Aenitis Technology enhance bioproduction?
It offers significant advantages such as increased recovery yields, reduced processing costs, and improved cell quality, crucial for applications in cell therapy.
What are the future plans for Aenitis?
Aenitis aims to commercialize its technologies, expand into international markets, and continue to innovate within the fields of biomanufacturing and cell therapy.
